These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33332430)

  • 21. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M; Conticini E; Bergantini L; Mazzei MA; Bellisai F; Selvi E; Cameli P; Frediani B; Bargagli E
    Tissue Cell; 2024 Oct; 90():102516. PubMed ID: 39137538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
    Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
    Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seasonal fluctuation of serum Krebs von den Lungen-6 levels in systemic sclerosis-associated interstitial lung disease.
    Hirose H; Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Harigai M; Kawaguchi Y
    Int J Rheum Dis; 2024 Jul; 27(7):e15254. PubMed ID: 38973340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
    Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study.
    Wakamatsu K; Nagata N; Kumazoe H; Hara M; Asai S; Noda N; Kiyotani R; Fukui I; Tatsuta M; Katahira K; Akasaki T; Maki S; Miyamoto K; Otsuka J; Izumi M; Kawasaki M; Yamada H
    BMC Pulm Med; 2024 Aug; 24(1):404. PubMed ID: 39174992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
    Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
    Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.
    Kamiya Y; Fujisawa T; Kono M; Nakamura H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Sumikawa H; Johkoh T; Yasui H; Hozumi H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    Respir Med; 2019 Nov; 159():105811. PubMed ID: 31710871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Liang B; Zhang Y; Ke D; Yan R; Jiang MN; Li L; Zhang LX; Zhao XG; Yuan GP; Xu B; Liu XM
    Immunol Invest; 2024 Aug; 53(6):989-1000. PubMed ID: 38900045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
    Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
    Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
    Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
    BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
    Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The diagnostic value of serum KL-6 in connective tissue disease associated interstitial lung disease].
    Wu X; Wu LJ; Luo CN; Shi YM; Zou JM; Meng XY
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3172-3175. PubMed ID: 31694110
    [No Abstract]   [Full Text] [Related]  

  • 34. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
    Avouac J; Cauvet A; Steelandt A; Shirai Y; Elhai M; Kuwana M; Distler O; Allanore Y
    PLoS One; 2020; 15(5):e0232978. PubMed ID: 32384128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study.
    Kilinc AA; Arslan A; Yildiz M; Kucur M; Adrovic A; Barut K; Sahin S; Cokugras H; Kasapcopur O
    Rheumatol Int; 2020 Oct; 40(10):1701-1706. PubMed ID: 31784789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.
    Shin B; Oh YJ; Kim J; Park SG; Lee KS; Lee HY
    BMC Pulm Med; 2024 Oct; 24(1):523. PubMed ID: 39427156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
    Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
    Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.